314 related articles for article (PubMed ID: 35478418)
1. AFF3 is a novel prognostic biomarker and a potential target for immunotherapy in gastric cancer.
Zeng Y; Zhang X; Li F; Wang Y; Wei M
J Clin Lab Anal; 2022 Jun; 36(6):e24437. PubMed ID: 35478418
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a necroptosis-related gene prognostic score to predict prognosis and efficiency of immunotherapy in gastric cancer.
Xia Y; Zhang R; Wang M; Li J; Dong J; He K; Guo T; Ju X; Ru J; Zhang S; Sun Y
Front Immunol; 2022; 13():977338. PubMed ID: 36159818
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.
Ma W; Li W; Xu L; Liu L; Xia Y; Yang L; Da M
Pathol Oncol Res; 2021; 27():1609852. PubMed ID: 34566519
[No Abstract] [Full Text] [Related]
4. Construction of a gene model related to the prognosis of patients with gastric cancer receiving immunotherapy and exploration of COX7A1 gene function.
Wang SY; Wang YX; Shen A; Yang XQ; Liang CC; Huang RJ; Jian R; An N; Xiao YL; Wang LS; Zhao Y; Lin C; Wang CP; Yuan ZP; Yuan SQ
Eur J Med Res; 2024 Mar; 29(1):180. PubMed ID: 38494472
[TBL] [Abstract][Full Text] [Related]
5. The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer.
Mak TK; Li X; Huang H; Wu K; Huang Z; He Y; Zhang C
Front Immunol; 2022; 13():951214. PubMed ID: 35967313
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
7. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
Front Oncol; 2021; 11():607224. PubMed ID: 34026603
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
9. Integrated bioinformatics analysis for conducting a prognostic model and identifying immunotherapeutic targets in gastric cancer.
Liu Y; Li D; Chen Y; Liu Y; Lin Y; Huang X; Wu T; Wang C; Ding J
BMC Bioinformatics; 2023 May; 24(1):191. PubMed ID: 37161430
[TBL] [Abstract][Full Text] [Related]
10. Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance.
Zhang AZ; Yuan X; Liang WH; Zhang HJ; Li Y; Xie YF; Li JF; Jiang CH; Li FP; Shen XH; Pang LJ; Zou H; Zhou WH; Li F; Hu JM
Front Cell Dev Biol; 2021; 9():762029. PubMed ID: 35252217
[TBL] [Abstract][Full Text] [Related]
11. Role of CXCR4 as a Prognostic Biomarker Associated With the Tumor Immune Microenvironment in Gastric Cancer.
Gu Y; Gu W; Xie R; Chen Z; Xu T; Fei Z
Front Cell Dev Biol; 2021; 9():654504. PubMed ID: 34568309
[No Abstract] [Full Text] [Related]
12. PDGFRB is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer.
Liu B; Xiao X; Lin Z; Lou Y; Zhao L
Cancer Biomark; 2022; 34(2):251-264. PubMed ID: 34958001
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
Liu Z; Miao J
Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
[TBL] [Abstract][Full Text] [Related]
14. Identification of the Expression of TIE1 and Its Mediated Immunosuppression in Gastric Cancer.
Gong Z; Zheng Q; Li B; Wang H; Chen H; Lin S
J Cancer; 2024; 15(10):2994-3009. PubMed ID: 38706903
[No Abstract] [Full Text] [Related]
15. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
Hu B; Meng Y; Qu C; Wang BY; Xiu DR
Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
17. Identification of N7-methylguanosine related subtypes and construction of prognostic model in gastric cancer.
Li X; Dong H; Chen L; Wang Y; Hao Z; Zhang Y; Jiao Y; Zhao Z; Peng X; Zhan X
Front Immunol; 2022; 13():984149. PubMed ID: 36300121
[TBL] [Abstract][Full Text] [Related]
18. CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer.
Hou W; Kong L; Hou Z; Ji H
BMC Med Genomics; 2022 Oct; 15(1):225. PubMed ID: 36316684
[TBL] [Abstract][Full Text] [Related]
19. Integrated pan-cancer analysis and experimental verification of the roles of tropomyosin 4 in gastric cancer.
Guo Q; Zhao L; Yan N; Li Y; Guo C; Dang S; Shen X; Han J; Luo Y
Front Immunol; 2023; 14():1148056. PubMed ID: 36993958
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of a 14 immune-related gene pair signature to predict the prognosis and immune features of gastric cancer.
Liu C; Chen B; Huang Z; Hu C; Jiang L; Zhao C
Int Immunopharmacol; 2020 Dec; 89(Pt B):107074. PubMed ID: 33049494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
